This news release is available in German.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has approved funding for six new clinical trials. This was decided by the Senate during its December meeting. Four other clinical trials were approved by the Senate in June. The topics of the ten contributions to medical research cover the fields of surgery, nephrology, gastroenterology, ophthalmology, dentistry, hospital hygiene and psychotherapy. The trials will investigate, among other topics, new therapeutic procedures for esophageal cancer and acute kidney failure, the role of cannabis in the management of tic disorders, and the treatment of obesity. Over 3,000 patients will participate in the trials.
The DFG's clinical trials programme enables researchers to address current, urgent questions in patient-oriented clinical research within the framework of a controlled interventional trial. All the approved trials are prospective and confirmatory trials on new procedures. This encompasses therapy trials, including pharmacological trials, as well as prognostic and diagnosis trials in phases II-IV.
The ten trials will receive a total of 13.1 million euros in funding for an initial period of three years. In total the DFG has already approved more than 80 clinical trials through this programme.
The topics of the new clinical trials (in alphabetical order by principal investigator):
Private lecturer Dr. Christian Bojarski, Charité - Universitätsmedizin Berlin
Prospective, double-blind diagnostic study of confocal laser endomicroscopy (CLE) for wheat sensitivity (WS) in patients with irritable bowel syndrome
Professor Dr. Iris F. Chaberny, University Hospital Leipzig
EFFECT of daily washing with Octenidine impregnated wash-cloths on the incidence of nosocomial infections in intensive care - a cross-over trial randomising intensive care units
Professor Dr. Sascha Fauser, University Hospital Cologne
Prophylactic intraoperative adjuvant therapy with 5-fluorouracil and low molecular weight heparin for the prevention of proliferative vitreoretinopathy (PVR) in high-risk patients with primary rhegmatogenous retinal detachment
Professor Dr. Petra Christine Gierthmühlen, Medical Center - University of Freiburg
CAD/CAM composite vs ceramic minimal invasive therapeutical intervention of severe non carious lesions: Clinical performance and quality of life improvement
Private lecturer Dr. Albrecht Hoffmeister, University Hospital Leipzig
A multi-centred, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liner vs intragastric balloons vs a sham procedure
Professor Dr. Ulrich T. Hopt, Medical Center - University of Freiburg
Perioperative chemotherapy (FLOT Protocol) compared with neoadjuvant chemoradiation (CROSS Protocol) in patients with adenocarcinoma of the esophagus
Professor Dr. Kirsten Müller-Vahl, Hannover Medical School
Randomized double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders
Professor Dr. Christian Plewnia, University Hospital Tübingen
Treatment of auditory hallucinations in schizophrenia with bilateral theta burst stimulation
Professor Dr. Thomas Seufferlein, Ulm University Medical Center
Allogenic microbiota-reconstitution (AMR) for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
Professor Dr. Alexander Zarbock, University Hospital Münster
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial)
DFG Press and Public Relations, Tel. +49 228 885-2443, firstname.lastname@example.org
DFG programme contacts:
Dr. Katja Großmann, Tel. +49 228 885-2565, Katja.Grossmann@dfg.de
Dr. Eckard Picht, Tel. +49 228 885-2028, Eckard.Picht@dfg.de
Detailed information will also be provided by the principal investigators of the clinical trials.
For more information about the DFG's programme for clinical trials, please visit: